Related Experiment Video
Updated: May 13, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Update on in vitro cytotoxicity assays for drug development
Andrew L Niles1, Richard A Moravec, Terry L Riss
1Senior Research Scientist Promega Corporation, Research and Development, 2800 Woods Hollow Road, Madison, Wisconsin, 53711, USA +1 608 247 4330, ext. 1447 ; +1 608 298 4818 ; andrew.niles@promega.com.
In vitro cytotoxicity testing is key for drug discovery. Multi-parametric assays combining viability and cytotoxicity markers offer improved data quality over single-parameter methods.
Area of Science:
- Pharmacology
- Biotechnology
- Drug Discovery
Background:
- In vitro cytotoxicity testing is essential for ranking compounds in drug discovery.
- Assay technology selection depends on specific research objectives.
Purpose of the Study:
- To evaluate popular and practical assay technologies for high-throughput screening (HTS) in drug discovery.
- To discuss considerations for HTS assay utility, including sensitivity, scalability, robustness, and cost-effectiveness.
Main Methods:
- Focus on three primary assay classes for HTS drug discovery: metabolism reductase activity, bioluminescent ATP assays, and released enzyme cytotoxicity assays.
- Briefly discuss multi-parametric technologies.
Main Results:
- Each assay method possesses distinct advantages and disadvantages.
- Single-parameter assays have inherent limitations.
Conclusions:
- Multi-parametric assays integrating both viability and cytotoxicity markers can overcome the limitations of single-parameter approaches.
- Careful consideration of assay characteristics is crucial for successful HTS drug discovery.
Related Concept Videos
In Vitro Drug Release Testing: Overview, Development and Validation
Drug Product Performance: In Vitro–In Vivo Correlation
In Vitro Drug Dissolution: Compendial Testing Models I
In Vitro Drug Dissolution: Alternative Methods
In Vitro Drug Dissolution: Compendial Testing Models II

